$STML $22.66 Bought a small position @ $21.39, appears to have bottomed.
Balance Sheet Total Cash (mrq): 87.67M Total Cash Per Share (mrq): 6.93 Total Debt (mrq): 0.00 Total Debt/Equity (mrq): N/A Current Ratio (mrq): 31.09 Book Value Per Share (mrq): 6.81
Share Statistics Avg Vol (3 month)3: 219,929 Avg Vol (10 day)3: 201,762 Shares Outstanding5: 12.66M Float: 9.62M % Held by Insiders1: 9.68% % Held by Institutions1: 11.20% Shares Short (as of Jan 15, 2014)3: 424.19K Short Ratio (as of Jan 15, 2014)3: 3.00 Short % of Float (as of Jan 15, 2014)3: 7.50%
Price Target Summary Mean Target: 33.75 Median Target: 38.00 High Target: 50.00 Low Target: 9.00 No. of Brokers: 4 Data provided by Thomson/First Call
Upgrades & Downgrades History Date Research Firm Action From To Aug 29, 2013 Jefferies Initiated Buy Jul 29, 2013 Roth Capital Initiated Buy Jun 18, 2013 Ladenburg Thalmann Initiated Buy Mar 18, 2013 Aegis Capital Initiated Buy Feb 12, 2013 WBB Securities Initiated Sell
NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30 AM ET. The conference will be held at the Waldorf Astoria in New York on February 10-11, 2014. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
NEW YORK, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 PM ET. The conference will be held at the Waldorf Astoria in New York City. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.